Drugs / glasmacinal
glasmacinal
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06677918 | Feb → Aug 2025 | — | EpiEndo Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06118684 | Oct 2023 → Jan 2024 | chronic obstructive pulmonary disease | EpiEndo Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05516316 | Oct 2022 → Jun 2023 | chronic obstructive pulmonary disease | EpiEndo Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04819854 | Apr 2021 → Mar 2022 | adult acute lymphoblastic leukemia | EpiEndo Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05572333 | Nov 2022 → Nov 2023 | chronic obstructive pulmonary disease | EpiEndo Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glasmacinal | “EP395 (glasmacinal), a novel macrolide, is being developed as a treatment to reduce exacerbations of COPD without inducing antimicrobial resistance.” PMID 42206016 ↗ May 20262“glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions.” PMID 41845869 ↗ Mar 2026 “glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions.” PMID 41845869 ↗ Mar 2026 |
| Known as | EP395 | “glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions.” PMID 41845869 ↗ Mar 2026 |
| Known as | EP395 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068055 ↗ |
| Modality | Small molecule | “oral anti-inflammatory macrolide” PMID 41845869 ↗ Mar 2026 |
| Route | Oral | “administered by oral capsules” NCT04819854 ↗ |